Literature DB >> 12466133

Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis.

Mauro Abbate1, Carla Zoja, Marina Morigi, Daniela Rottoli, Stefania Angioletti, Susanna Tomasoni, Cristina Zanchi, Lorena Longaretti, Roberta Donadelli, Giuseppe Remuzzi.   

Abstract

Chronic diseases of the kidney have a progressive course toward organ failure. Common pathway mechanisms of progressive injury, irrespectively of the etiology of the underlying diseases, include glomerular capillary hypertension and enhanced passage of plasma proteins across the glomerular capillary barrier because of impaired permselective function. These changes are associated with podocyte injury and glomerular sclerosis. Direct evidence for causal roles is lacking, particularly for the link between intraglomerular protein deposition and sclerosing reaction. Because transforming growth factor-beta1 (TGF-beta1) is the putative central mediator of scarring, we hypothesized that TGF-beta1 can be up-regulated by protein overload of podocytes thereby contributing to sclerosis. In rats with renal mass reduction, protein accumulation in podocytes as a consequence of enhanced transcapillary passage preceded podocyte dedifferentiation and injury, increase in TGF-beta1 expression in podocytes, and TGF-beta1-dependent activation of mesangial cells. Angiotensin-converting enzyme inhibitor prevented both accumulation of plasma proteins and TGF-beta1 overexpression in podocytes and sclerosis. Albumin load on podocytes in vitro caused loss of the synaptopodin differentiation marker and enhanced TGF-beta1 mRNA and protein. Conditioned medium of albumin-stimulated podocytes induced a sclerosing phenotype in mesangial cells, an effect mimicked by TGF-beta1 and blocked by anti-TGF-beta1 antibodies. Thus, the passage of excess plasma proteins across the glomerular capillary wall is the trigger of podocyte dysfunction and of a TGF-beta1-mediated mechanism underlying sclerosis. Agents to reduce TGF-beta1, possibly combined with angiotensin blockade, should have priority in novel approaches to treatment of progressive nephropathies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466133      PMCID: PMC1850904          DOI: 10.1016/s0002-9440(10)64495-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

1.  Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease.

Authors:  M Abbate; C Zoja; D Rottoli; D Corna; N Perico; T Bertani; G Remuzzi
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

2.  AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells.

Authors:  Cora Weigert; Ulrich Sauer; Katrin Brodbeck; Andreas Pfeiffer; Hans U Häring; Erwin D Schleicher
Journal:  J Am Soc Nephrol       Date:  2000-11       Impact factor: 10.121

3.  TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain.

Authors:  B L Riser; S Ladson-Wofford; A Sharba; P Cortes; K Drake; C J Guerin; J Yee; M E Choi; P R Segarini; R G Narins
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

4.  Synaptopodin expression in idiopathic nephrotic syndrome of childhood.

Authors:  T Srivastava; R E Garola; J M Whiting; U S Alon
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

5.  Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals.

Authors:  G Remuzzi; C Zoja; E Gagliardini; D Corna; M Abbate; A Benigni
Journal:  J Am Soc Nephrol       Date:  1999-07       Impact factor: 10.121

6.  Congenital nephrotic syndrome in mice lacking CD2-associated protein.

Authors:  N Y Shih; J Li; V Karpitskii; A Nguyen; M L Dustin; O Kanagawa; J H Miner; A S Shaw
Journal:  Science       Date:  1999-10-08       Impact factor: 47.728

7.  Location of gp330/alpha 2-m receptor-associated protein (alpha 2-MRAP) and its binding sites in kidney: distribution of endogenous alpha 2-MRAP is modified by tissue processing.

Authors:  M Abbate; D Bachinsky; G Zheng; I Stamenkovic; M McLaughlin; J L Niles; R T McCluskey; D Brown
Journal:  Eur J Cell Biol       Date:  1993-06       Impact factor: 4.492

Review 8.  How does glomerular epithelial cell injury contribute to progressive glomerular damage?

Authors:  H G Rennke
Journal:  Kidney Int Suppl       Date:  1994-02       Impact factor: 10.545

9.  Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney.

Authors:  Y Isaka; Y Fujiwara; N Ueda; Y Kaneda; T Kamada; E Imai
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

10.  Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts.

Authors:  A Desmoulière; A Geinoz; F Gabbiani; G Gabbiani
Journal:  J Cell Biol       Date:  1993-07       Impact factor: 10.539

View more
  36 in total

Review 1.  The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy.

Authors:  Raghu V Durvasula; Stuart J Shankland
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

2.  In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy.

Authors:  Ling Zheng; Raja Sinniah; Stephen I-Hong Hsu
Journal:  Virchows Arch       Date:  2005-10-05       Impact factor: 4.064

3.  Podocyte injury damages other podocytes.

Authors:  Taiji Matsusaka; Eric Sandgren; Ayumi Shintani; Valentina Kon; Ira Pastan; Agnes B Fogo; Iekuni Ichikawa
Journal:  J Am Soc Nephrol       Date:  2011-06-30       Impact factor: 10.121

Review 4.  Role of albumin and its modifications in glomerular injury.

Authors:  Shipra Agrawal; William E Smoyer
Journal:  Pflugers Arch       Date:  2017-07-22       Impact factor: 3.657

Review 5.  Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.

Authors:  Min Jun; Tanvir Chowdhury Turin; Mark Woodward; Vlado Perkovic; Hiddo J Lambers Heerspink; Braden J Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2015-01-02       Impact factor: 10.121

Review 6.  Podocyte-actin dynamics in health and disease.

Authors:  Luca Perico; Sara Conti; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

7.  TGFβ-Induced Actin Cytoskeleton Rearrangement in Podocytes Is Associated with Compensatory Adaptation of Mitochondrial Energy Metabolism.

Authors:  Gabriella Casalena; Erwin Bottinger; Ilse Daehn
Journal:  Nephron       Date:  2015-11-28       Impact factor: 2.847

8.  Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders.

Authors:  Laura Lasagni; Lara Ballerini; Maria Lucia Angelotti; Eliana Parente; Costanza Sagrinati; Benedetta Mazzinghi; Anna Peired; Elisa Ronconi; Francesca Becherucci; Daniele Bani; Mauro Gacci; Marco Carini; Elena Lazzeri; Paola Romagnani
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

9.  Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury.

Authors:  Mauro Abbate; Carla Zoja; Daniela Corna; Daniela Rottoli; Cristina Zanchi; Nadia Azzollini; Susanna Tomasoni; Silvia Berlingeri; Marina Noris; Marina Morigi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

10.  Diabetic albuminuria is due to a small fraction of nephrons distinguished by albumin-stained tubules and glomerular adhesions.

Authors:  Patricia M Kralik; Yunshi Long; Ye Song; Lu Yang; Haiyang Wei; Susan Coventry; Shirong Zheng; Paul N Epstein
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.